GeneWorx Capital - Blog , GeneWorx Discovery SeriesGeneWorx Capital - Blog , GeneWorx Discovery Serieshttps://www.geneworxcapital.com/blogs/geneworx-discovery-seriesFri, 16 Jan 2026 00:25:15 -0800http://zoho.com/sites/<![CDATA[Fighting the Cardiovascular Disease Pandemic]]>https://www.geneworxcapital.com/blogs/post/Fighting-the-Cardiovascular-Disease-PandemicCardiovascular disease (CVD) is a pandemic --- causes one in every four deaths in the U.S., one in three worldwide.  Now there is a new weapon aga ]]>

Breakthrough Precision Treatment Tools 
and Next-Generation Drug Development

Cardiovascular disease (CVD) is a pandemic --- causes one in every four deaths in the U.S., one in three worldwide. 

Now there is a new weapon against this pandemic --- a non-invasive imaging diagnostic that can diagnose cardiovascular disease early before it's too late, enabling precision treatment and the development of next generation drugs for early treatment.

In this video you will learn about:
  • Reducing clinical trial costs and duration by 50% through highly specific non-invasive cardiovascular disease assessment 
  • Ushering in the new era of true CVD precision medicine treatment made possible by applying AI to CVD plaque morphology analytics
  • Optimizing patient treatments and outcomes using predictive non-invasive CVD biomarker measurements
  • Slowing and preventing CVD progression towards interventional care with earlier diagnosis and treatment
  • Improving clinical trial patient selection with stroke/MACE prediction that is 35%+ more accurate vs. current standard of care 
  • Eliminating unnecessary cath lab procedures by overcoming inaccuracies in today's CVD first-line diagnostics 
  • Never-before-possible plaque morphology measurements reveal treatment effectiveness of new CVD drug in ongoing clinical trial

Presenters: 

Matthew Budoff, MD - Investigator, The Lundquist Institute; Professor of Medicine, David Geffen School of Medicine at UCLA; Program Director and Director of Cardiac CT, Division of Cardiology, Harbor-UCLA Medical Center
Dr. Budoff has author or coauthored more than 50 books and book chapters and more than 2000 articles and abstracts. He has received numerous research grants from the National Institutes of Health and has been invited to lecture at cardiology conferences around the world. In addition to his 2015 appointment as the Endowed Chair of Preventive Cardiology at Harbor-UCLA Medical Center, he has been recognized for his work by the Society of Cardiovascular Computed Tomography, from which he received the Gold Medal Award and recently designated as Master of the Society of Cardiovascular Computed Tomography (MSCCT), and has been inducted into the European Academy of Sciences. Dr. Budoff has been named to “America’s Top Doctors” for each of the past 9 years. In 2011, he was named a US News Top Doctor for cardiology, was awarded the Albert Nelson Marquis Lifetime Achievement Award in 2018 and named to “The world’s most influential scientific researchers” in 2018 and 2019. lundquist.org/matthew-budoff-md   

Andrew J. Buckler - Founder, President, CTO of Elucid 
A true pioneer in molecular and quantitative imaging, Buckler has been researching, studying, and publishing in the field of non-invasive imaging modalities for more than 30 years. He has collaborated with researchers around the world to publish more than 70 peer-reviewed journal articles on biomedical and molecular imaging. Additionally, he has led large engineering teams at Eastman Kodak, Hewlett Packard, Siemens, and Philips. He and his teams have invented, developed, and launched dozens of products, generating well over a billion dollars in revenue. Buckler is also the program director and co-chair of the Quantitative Imaging Biomarkers Alliance. QIBA was formed to unite researchers, healthcare professionals, and the industry to advance quantitative imaging and the use of imaging biomarkers in clinical trials and clinical practice. The scope including both definition of methodology as well as the application of that methodology to selected biomarkers. 
ElucidVivo clinical solutions provide comprehensive and accurate clinical insights, based on ground-truth histology and machine learning, enabling unprecedented precision healthcare for vascular disease. 
elucidvivo.com     

Host: 

William Kazman - Founding Partner of GeneWorx Capital 
MIT-trained engineer/entrepreneur and enthusiast of the biological revolution and its accelerating global impact. Applying 30+ years of engineering and company-building skills to identify early stage biological innovations with disruptive potential, and help their inventors / scientists / entrepreneurs transform them into high value enterprises. 
GeneWorx Capital is a venture development firm in Cambridge, MA comprised of MIT technologists, former Wall Street VC investors and Silicon Valley entrepreneurs on a mission to accelerate the growth of emerging life science companies.
GeneWorxCapital.com

]]>Fri, 17 Dec 2021 15:47:04 +0000<![CDATA[Chemical Immunology and the Birth of a New Industry]]>https://www.geneworxcapital.com/blogs/post/GeneWorx-Discovery-Series-Chemical-ImmunologyChemical Immunology and the Birth of a New Industry - catalytic antibodies (catabodies) and irreversible antibodies (IrAbs) eliminate disease-causing proteins 1000x more powerfully than regular antibodies]]>

A Disruptive, New Approach for Developing Superior Drugs, 
Vaccines, and Diagnostics

Much of the science of immunology is concerned with two classes of molecules – 1) antigens that stimulate the immune system to produce adaptive antibodies, and 2) antibodies with weak chemical reactivity (Abs) that target toxic antigens for removal. But Darwinian evolution also created antibodies with more powerful chemical reactivity: 

  

catalytic antibodies (catabodies) and irreversible antibodies (IrAbs) that eliminate disease-causing proteins 1000x more powerfully than regular antibodies (Abs) 

  

A new synthetic biology platform harnesses this chemical power by making possible the selection of the catabodies and IrAbs in monoclonal form, and the ability to induce their synthesis using engineered vaccines (E-vaccines). Catabodies and IrAbs can be selected to target any protein that causes disease:

  • aging diseases - Alzheimer’s, TTR Amyloidosis, others
  • infectious diseases - HIV, Staph Aureus, COVID-19 and the next pandemic, others
  • cancer
  • autoimmune disease
  • others

  

In this video, renowned industry leaders discuss the science, commercial potential, and societal impact of this transformational technology:

  • What is the role of catabody and IrAb therapeutics in curing the most intractable diseases?
  • Will catabody-inducing E-vaccines be deployed to prevent infections by the most virulent microbes?   
  • What scientific and commercial challenges remain on the road ahead?
  • How long before catabodies, IrAbs and E-vaccines displace and surpass the $140B+ monoclonal antibody and $70B+ vaccine markets?
  • ...and more!

  

Panelists:

  

Sudhir Paul, Ph.D., CSO & Co-Founder of Covalent Bioscience

Discoverer of naturally occurring catabodies, inventor of synbio catabody discovery platform, over 200 publications

https://covalentbioscience.com/about-us/   

  

Anthony Rees, Professor Emeritus and Honorary DSc, University of Bath, UK

Antibody/catabody expert – wrote the book on antibodies: “The Antibody Molecule – from Anti-Toxins to Therapeutic Antibodies” 

http://reesconsultingab.com/   

  

Joel Buxbaum, MD, Professor Emeritus, Scripps Research

Expert on Alzheimers, TTR amyloidosis and other aging diseases 

https://www.scripps.edu/faculty/buxbaum/   

  

Seth Pincus, MD, Professor Antibody Biology and Medicine, Montana State University

Infectious disease expert and authority on vaccines and antibodies 

https://chemistry.montana.edu/directory/2077781/seth-pincus   

  

Richard Massey, Ph.D., CEO & Co-Founder of Covalent Bioscience

Biotech serial entrepreneur and expert on commercial opportunities of catabodies, E-vaccines, and IrAbs

https://covalentbioscience.com/about-us/   

  

Host and Moderator:

  

William Kazman, Founding Partner of GeneWorx Capital

MIT engineer/entrepreneur and enthusiast of the biological revolution and its accelerating global impact

https://www.geneworxcapital.com/team

]]>Mon, 24 May 2021 21:06:54 +0000<![CDATA[A Swine Solution - Harnessing the Power of the Pig ​in Pursuit of Cancer Therapies]]>https://www.geneworxcapital.com/blogs/post/GeneWorx-Discovery-Series-A-Swine-SolutionA Swine Solution – Harnessing the Power of the Pig ​in Pursuit of Cancer Therapies. Discover why and how pigs are becoming the must-have preclinical model for accelerating development of cancer therapies.]]>


Want to discover why and how pigs are becoming the must-have preclinical model for accelerating development of cancer therapies? 


In this video you will learn:
  • Unrivaled advantages of pigs vs traditional animal models
  • Why pigs are essential preclinical platforms for gene therapy, rare disease, pediatric cancers, and more
  • The "nuts-and-bolts" of genetically engineering pigs
  • Case study on how pigs have augmented  mouse models and enabled critical PK/PD studies for Neurofibromatosis Type 1
  • Harnessing human genetic drivers to induce solid tumors in pigs
  • Using pigs for biomarker discovery
  • Late breaking!... new models for Glioblastoma and hepatocellular carcinoma
  • Getting started…. planning for pig models in your new studies


Speaker:  Adrienne Watson, PhD, VP R&D of Surrogen (division of Recombinetics)


Expert in gene-editing technology for swine models of human diseases with a focus on cancer, neurodegenerative diseases, and regenerative medicine. Utilized Sleeping Beauty transposon system in animal models to develop new animal models, uncover targeted therapy candidates, and identify novel cancer genes and pathways. Ph.D. in Molecular, Cellular, Developmental Biology and Genetics at the Univ MN. Post-Doc at University of Minnesota Masonic Cancer Center. 

Surrogen is a world leader in gene edited pigs and disease models to accelerate new therapeutics and med devices development.


Host:  William Kazman, Founding Partner of GeneWorx Capital


MIT-trained engineer/entrepreneur and enthusiast of the biological revolution and its accelerating global impact. Applying 30+ years of engineering and company-building skills to identify early stage biological innovations with disruptive potential, and help their inventors/scientists/entrepreneurs transform them into high value enterprises. 

GeneWorx Capital is a venture development firm in Cambridge, MA comprised of MIT technologists, former Wall Street VC investors and Silicon Valley entrepreneurs on a mission to accelerate the growth of emerging life science companies. 


]]>Sun, 29 Nov 2020 21:42:55 +0000<![CDATA[New Synthetic Biology Platform ​Delivers Massively Superior ​Drug, Vaccine, and Diagnostic Candidates]]>https://www.geneworxcapital.com/blogs/post/GeneWorx-Discovery-Series-New-Synthetic-Biology-Platform-Delivers-Massively-Superior-MedicinesDarwinian evolution created rare catalytic antibodies that eliminate disease-causing proteins 1000x more powerfully than regular antibodies. Synthetic biology harnesses them to create next generation therapies, vaccines, and diagnostics.]]>


Darwinian evolution created rare catalytic antibodies that eliminate disease-causing proteins 1000x more powerfully than regular antibodies. Synthetic biology harnesses them to create next generation therapies, vaccines, and diagnostics. 


In this video you will learn about: 

  • The discovery of naturally occurring antibodies with powerful, disease-fighting enzymatic activity 
  • The synthetic biology platform that makes possible the selection and induction of such catabodies that target any disease-causing protein 
  • Case study: creating the world’s first HIV vaccine that destroys strains from around the world. 
  • Case study: breakthrough Alzheimer’s therapy that improves brain function 
  • Massively improving immunoassay sensitivity with irreversible antibodies for any target 
  • What the future holds…. unleashing the enormous therapeutic potential of catabodies for neurology, cardiovascular, allergy, autoimmune, cancer, infectious disease, and more 


Speaker:  Sudhir Paul, Ph.D., CSO & Co-Founder of Covalent Bioscience 


Paul’s work as a Professor at the Universities of Nebraska and Texas has brought catabodies/E-vaccines from chemical curiosities to the threshold of medical use. His research has been funded continuously by the NIH, non-profit foundations and biotech companies since 1983. He discovered harmful catabodies in autoimmune disease, progressing to devising Covalent’s synthetic biology platform for generating catabodies and E-vaccines for disease treatment and prevention. He has authored more than 200 original research articles and edited several books. Paul co-founded Covalent Bioscience. In 2018, he moved fulltime to Covalent to translate his know-how and inventions for medical benefit. 


Covalent Bioscience is a Texas-based company with a disruptive new approach for developing superior drugs, vaccines and diagnostsics based on catabodies, irreversible antibodies, and E-vaccines (electrophilic vaccine). Covalent’s patented technology can deliver novel catabodies, irreversible antibodies, and E-vaccines against any pre-defined target in under 6 months. 


Host:  William Kazman, Founding Partner of GeneWorx Capital 


MIT-trained engineer/entrepreneur and enthusiast of the biological revolution and its accelerating global impact. Applying 30+ years of engineering and company-building skills to identify early stage biological innovations with disruptive potential, and help their inventors/scientists/entrepreneurs transform them into high value enterprises. 


GeneWorx Capital is a venture development firm in Cambridge, MA comprised of MIT technologists, former Wall Street VC investors and Silicon Valley entrepreneurs on a mission to accelerate the growth of emerging life science companies.


]]>Wed, 04 Nov 2020 19:50:55 +0000